RXG is positioning itself to capture a “royalty stream” (discount/rebate) from commercially approved immunotherapies without direct development risk.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free